Skip to main content Accessibility help
×
×
Home

Pharmacological treatment of mixed states

  • Alessandro Cuomo (a1), Viktoriya L. Nikolova (a2), Nefize Yalin (a2), Danilo Arnone (a2), Andrea Fagiolini (a3) and Allan H. Young (a2)...

Abstract

Mixed states in bipolar disorder have been neglected, and the data concerning treatment of these conditions have been relatively obscure. To address this, we systematically reviewed published pharmacological treatment data for “mixed states/episodes” in mood disorders, including “with mixed features” in DSM–5. We searched PubMed, MEDLINE, The Cochrane Library, clinicaltrials.gov, and controlled-trials.com (with different combinations of the following keywords: “mixed states/features,” “bipolar,” “depressive symptoms/bipolar depression,” “manic symptoms,” “treatment,” “DSM–5”) through to October 2016. We applied a quality-of-evidence approach: first-degree evidence=randomized placebo-controlled studies of pharmacological interventions used as monotherapy; second-degree evidence=a similar design in the absence of a placebo or of a combination therapy as a comparative group; third-degree evidence=case reports, case series, and reviews of published studies. We found very few primary double-blind, placebo-controlled studies on the treatment of mixed states: the preponderance of available data derives from subgroup analysis performed on studies that originally involved manic patients. Future research should study the effects of treatments in mixed states defined using current criteria.

Copyright

Corresponding author

*Address for correspondence: Professor Allan H. Young, Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, PO72 De Crespigny Park, London SE5 8AF, United Kingdom. Email: (Allan.Young@kcl.ac.uk)

Footnotes

Hide All

We thank Ms. Caroline Loveland for her help in preparing this manuscript. Dr. Danilo Arnone is supported by the Academy of Medical Sciences (AMS-SGCL8).

This paper represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London, the Maudsley NHS Foundation Trust, and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Footnotes

References

Hide All
1. Swann, AC, Lafer, B, Perugi, G, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013; 170(1): 3142. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2012.12030301. Accessed January 8, 2017.
2. Vieta, E, Valenti, M. Mixed states in DSM–5: implications for clinical care, education, and research. J Affect Disord. 2013; 148(1): 2836. Epub ahead of print Apr 2. http://www.jad-journal.com/article/S0165-0327(13)00232-2/pdf. Accessed January 8, 2017.
3. Castle, DJ. Bipolar mixed states: still mixed up? Curr Opin Psychiatry. 2014; 27(1): 3842.
4. Houston, JP, Ahl, J, Meyers, AL, Kaiser, CJ, Tohen, M, Baldessarini, RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry. 2006; 67(8): 12461252.
5. Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151(4): W65W94. Epub ahead of print Jul 20.
6. Tohen, M, Sanger, TM, McElroy, SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999; 156(5): 702709. http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.156.5.702. Accessed January 8, 2017.
7. Tohen, M, Jacobs, TG, Grundy, SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000; 57(9): 841849. http://jamanetwork.com/journals/jamapsychiatry/fullarticle/205739. Accessed January 8, 2017.
8. Novick, D, Reed, C, Haro, JM, et al. Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010; 25(5): 257263.
9. Perlis, RH, Baker, RW, Zarate, CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry. 2006; 67(11): 17471753.
10. Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, et al. A 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003; 60(12): 12181226. http://jamanetwork.com/journals/jamapsychiatry/fullarticle/208076. Accessed January 8, 2017.
11. Tohen, M, Greil, W, Calabrese, JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005; 162(7): 12811290. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.162.7.1281. Accessed January 8, 2017.
12. McIntyre, RS, Cohen, M, Zhao, J, Alphs, L, Macek, TA, Panagides, J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009; 11(8): 815826. Epub ahead of print Oct 14.
13. Tohen, M, Ketter, TA, Zarate, CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003; 160(7): 12631271. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.160.7.1263. Accessed January 8, 2017.
14. Tohen, M, Chengappa, KN, Suppes, T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004; 184: 337345. http://bjp.rcpsych.org/content/184/4/337.long. Accessed January 8, 2017.
15. Weisler, RH, Nolen, WA, Neijber, A, Hellqvist, A, Paulsson, B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J Clin Psychiatry. 2011; 72(11): 14521464.
16. Vieta, E, Suppes, T, Eggens, I, Persson, I, Paulsson, B, Brecher, M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008; 109(3): 251263. Epub ahead of print Jun 24.
17. Suppes, T, Vieta, E, Liu, S, Brecher, M, Paulsson, B. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009; 166(4): 476488. Epub ahead of print Mar 16. http://ajp.psychiatryonline.org/doi/pdfplus/10.1176/appi.ajp.2008.08020189. Accessed January 8, 2017.
18. Keck, PE Jr, Marcus, R, Tourkodimitris, S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003; 160(9): 16511658. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.160.9.1651. Accessed January 8, 2017.
19. Keck, PE, Orsulak, PJ, Cutler, AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord. 2009; 112(1–3): 3649. Epub ahead of print Oct 2, 2008.
20. Young, AH, Oren, DA, Lowy, A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry. 2008, 194(1): 4048. http://bjp.rcpsych.org/content/194/1/40.long. Accessed January 8, 2017.
21. Keck, PE Jr, Calabrese, JR, McIntyre, RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007; 68(10): 14801491.
22. Findling, RL, Nyilas, M, Forbes, RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009; 70(10): 14411451.
23. Vieta, E, Bourin, M, Sanchez, R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005; 187: 235242. http://bjp.rcpsych.org/content/187/3/235.long. Accessed January 8, 2017.
24. Vieta, E, T’Joen, C, McQuade, RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008; 165(10): 13161325. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2008.07101560. Accessed January 8, 2017.
25. Marcus, R, Khan, A, Rollin, L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 2011; 13(2): 133144.
26. Vieta, E, Owen, R, Baudelet, C, McQuade, RD, Sanchez, R, Marcus, RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin. 2010; 26(6): 14851496.
27. McIntyre, RS, Cohen, M, Zhao, J, Alphs, L, Macek, TA, Panagides, J. Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study. J Affect Disord. 2010; 126(3): 358365.
28. McIntyre, RS, Cohen, M, Zhao, J, Alphs, L, Macek, TA, Panagides, J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010; 122(1–2): 2738.
29. Bowden, CL, Vieta, E, Ice, KS, Schwartz, JH, Wang, PP, Versavel, M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry. 2010; 71(2): 130137.
30. Keck, PE Jr, Versiani, M, Potkin, S, West, SA, Giller, E, Ice, K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003; 160(4): 741748. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.160.4.741. Accessed January 8, 2017.
31. Potkin, SG, Keck, PE Jr, Segal, S, Ice, K, English, P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005; 25(4): 301310.
32. Vieta, E, Nuamah, IF, Lim, P, et al. A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010; 12(3): 230243.
33. Berwaerts, J, Xu, H, Nuamah, I, Lim, P, Hough, D. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose–response study. J Affect Disord. 2012; 136(1–2): e51e60. Epub ahead of print Jul 10, 2010.
34. Khanna, S, Vieta, E, Lyons, B, Grossman, F, Eerdekens, M, Kramer, M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005; 187: 229234. http://bjp.rcpsych.org/content/187/3/229.long. Accessed January 8, 2017.
35. Sachs, GS, Greenberg, WM, Starace, A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disorders. 2015; 174: 296302. Epub ahead of print Nov 24, 2014. http://www.jad-journal.com/article/S0165-0327(14)00728-9/pdf. Accessed January 8, 2017.
36. Durgam, S, Starace, A, Li, D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015; 17(1): 6375. Epub ahead of print Jul 24, 2014.
37. Calabrese, JR, Keck, PE Jr, Starace, A, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015; 76(3): 284292.
38. Bowden, CL, Swann, AC, Calabrese, JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006; 67(10): 15011510.
39. Freeman, TW, Clothier, JL, Pazzaglia, P, Lesem, MD, Swann, AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992; 149(1): 108111.
40. Bowden, CL, Calabrese, JR, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003; 60(4): 392400. http://jamanetwork.com/journals/jamapsychiatry/fullarticle/207328. Accessed January 8, 2017.
41. Calabrese, JR, Bowden, CL, Sachs, G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003; 64(9): 10131024.
42. Perugi, G, Toni, C, Ruffolo, G, Sartini, S, Simonini, E, Akiskal, H. Clinical experience using adjunctive gabapentin in treatment-resistant bipolar mixed states. Pharmacopsychiatry. 1999; 32(4): 136141.
43. Suppes, T, Eudicone, J, McQuade, R, Pikalov, A 3rd, Carlson, B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord. 2008; 107(1–3): 145154. Epub ahead of print Sep 27, 2007.
44. Sachs, G, Sanchez, R, Marcus, R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006; 20(4): 536546. http://journals.sagepub.com/doi/pdf/10.1177/0269881106059693. Accessed January 8, 2017.
45. McIntyre, RS, Cohen, M, Zhao, J, Alphs, L, Macek, TA, Panagides, J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009; 11(7): 673686.
46. Suppes, T, Silva, R, Cucchiaro, J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016; 173(4): 400407. Epub ahead of print Nov 10, 2015.
47. Patkar, A, Gilmer, W, Pae, CU, et al. A 6-week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PloS One. 2012; 7(4): e34757. Epub ahead of print Apr 24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335844/. Accessed January 8, 2017.
48. Stahl, S, Lombardo, I, Loebel, A, Mandel, FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord. 2010; 122(1–2): 3945. Epub ahead of print Jul 17, 2009.
49. Suppes, T, McElroy, SL, Gilbert, J, Dessain, EC, Cole, JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry. 1992; 32(3): 270280.
50. Weisler, RH, Hirschfeld, R, Cutler, AJ, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs. 2006; 20(3): 219231.
51. Weisler, RH, Kalali, AH, Ketter, TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004; 65(4): 478484.
52. Weisler, RH, Keck, PE Jr, Swann, AC, Cutler, AJ, Ketter, TA, Kalali, AH. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005; 66(3): 323330.
53. Houston, JP, Tohen, M, Degenhardt, EK, Jamal, HH, Liu, LL, Ketter, TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study. J Clin Psychiatry. 2009; 70(11): 15401547. Epub ahead of print Sep 22.
54. Tohen, M, Chengappa, KN, Suppes, T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002; 59(1): 6269.
55. Baker, RW, Brown, E, Akiskal, HS, et al. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry. 2004; 185: 472478. http://bjp.rcpsych.org/content/185/6/472.long. Accessed January 8, 2017.
56. Benazzi, F, Berk, M, Frye, MA, Wang, W, Barraco, A, Tohen, M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry. 2009; 70(10): 14241431.
57. Suppes, T, Ketter, TA, Gwizdowski, IS, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord. 2013; 150(1): 3743. Epub ahead of print Mar 19.
58. Tohen, M, Calabrese, JR, Sachs, GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006; 163(2): 247256. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.163.2.247. Accessed January 8, 2017.
59. Tohen, M, Sutton, VK, Calabrese, JR, Sachs, GS, Bowden, CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord. 2009; 116(1–2): 4350. Epub ahead of print Dec 2, 2008.
60. Bowden, CL, Collins, MA, McElroy, SL, et al. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology. 2005; 30(10): 19321939. http://www.nature.com/npp/journal/v30/n10/pdf/1300788a.pdf. Accessed January 8, 2017.
61. Ketter, TA, Kalali, AH, Weisler, RH. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004; 65(5): 668673.
62. Carlson, BX, Ketter, TA, Sun, W, et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord. 2012; 14(1): 4153.
63. Woo, YS, Bahk, WM, Jon, DI, et al. Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea. Psychiatry Clin Neurosci. 2010; 64(1): 2837. Epub ahead of print Nov 4, 2009.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed